España
A blue la miro de reojo como a las otras de Car T, pero por algún lado leí, no recuerdo donde que su terapia curaría la anemia falciforme ( de entrada no se ni que es ni como se trata)
Cierto que MSTX esta muy avanzada, espero le saques ese buen pico y mas. Te imaginas a MSTX con la capitalización de Blue, bufff...
BLUE
Es normal, con el subidón que llevan eran carne de corto, tres semanas fuera de las Bollinger son mucha tela. Pero a la larga son buena opción, buen producto, buenos fundamentales, bastardo a favor, Erdys recomienda el producto. Es caballo ganador si la pillas en un buen dip.
ZGNX
Joer, superas los 30.
MSTX
Yo sigo hundido en el gas así que no la voy a aprovechar. Lo mio con las farmas en este momento es matar el tiempo a la espera de que venga el frío. :-S
OFF-topic
Por cierto y hablando de frío creo que ha vuelto el momento del carbón y a estos precios me quedo sin duda con ANR. Mucha deuda pero a cambio tiene mucho cash y reservas de carbón como para enterrar a sus acreedores. En 1'60 es una ganga. Ahora el riesgo/beneficio de WLT me parece peor. Vale lo mismo una accion de WLT que de ANR y ni tienen el mismo cash, ni la misma deuda ni las mismas reservas de carbón. ANR es un chollo de cara al frío.
Yo no recomiendo nada, te recuerdo que recomendé AMRN y GALE :((
GALE subirá. La cuestión es cuándo entrar. A mí me tienta mucho a estos niveles.
Con AMRN aprendimos todos que no se puede joder a las grandes farmas e ir en solitario impunemente. Igual algún día...
GALE
18-11-2014
Roth Capital affirms Galena Biopharma (Nasdaq: GALE) at Buy with a price target of $8 following an update on Phase 2 GALE-401 enrollment.
Reclutamiento completado GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
11-11-2014
Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients
Datos presentación oncológica 7-11-2014
Phase 1/2a trial of GALE-301, a Folate Binding Protein (FBP)-derived immunotherapy. Buenos datos de seguridad y eficacia. Además, el compuesto consigue un 38% de reducción de reaparición de tumores en los ovarios.
After a median follow-up of 13 months, there have been 11/22 (50%) recurrences in the control group compared to 9/29 (31%) recurrences in the vaccine group, a 38% reduction in relative risk of recurrence. The study was not powered for efficacy but rather, a clinical proof of concept study. GALE-301 generates a long lasting immune response, which generates tumor lysing CD8 T cells, bypassing the need for active receptor or ligand binding to generate efficacy.
Informe 6-11-2014
On January 12, 2014, we acquired exclusive worldwide license to develop and commercialize GALE 401 (anagrelide CR), a patented, controlled-release formulation of anagrelide, through our acquisition of Mills Pharmaceuticals, LLC (“Mills”) under a unit purchase agreement. Under the terms of the unit purchase agreement, we made an up-front cash payment of $2 million to the former Mills owners and also agreed to make additional contingent payments to the former owners upon the achievement of certain development milestones relating to GALE 401, including 2,000,000 shares of our common stock upon initiating the first clinical trial of GALE 401 in patients with essential thrombocythemia, or “ET,” and an additional 2,000,000 shares upon initiating a Phase 3 clinical study of GALE 401. The number of shares issuable upon the milestones is subject to increase based on a formula specified in the purchase agreement, up to a maximum of 3,000,000 shares for each milestone, in the event the five day average trailing closing price of our common stock (the “Average Price”) is less than $4.84 at the time the applicable milestone is achieved. Similarly, the number of shares issuable upon achievement of the milestones is subject to decrease based on such formula if the Average Price exceeds $6.84 at the time of achievement of the applicable milestone.
We achieved the milestone relating to the initiation of the first clinical trial of GALE-401 in the third quarter of 2014 and issued 3,000,000 shares of common stock to the former owners, the maximum under the unit purchase agreement as our five-day average trailing close price of our common stock was less than the low end of the collar of $4.84 . We will record as an addition to the GALE-401 intangible asset the fair value of the shares delivered in payment of each milestone under the Mills unit purchase agreement. The addition to the intangible asset for the fair value of the shares will increase our additional paid-in capital by the same amount, less the par value of the milestone shares. As a result of the achievement of the initiation of the first clinical trial of GALE-401, we recorded an addition to GALE-401 asset and additional paid in capital in the amount of $6.8 million , or the fair value of the shares issued. The milestone payments will have no effect on our net loss.
On July 17, 2014, we entered into a definitive license and supply agreement with MonoSol Rx, LLC (MonoSol) for the U.S. commercial rights to Zuplenz ® (ondansetron) Oral Soluble Film, an FDA approved product for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Refer to Note 12 for details of the transaction.
In conjunction with the acquisition of NeuVax TM , the company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (“MDACC”) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (“HJF”) which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee of $200,000 , a milestone payment of $200,000 upon commencing the Phase 3 PRESENT trial of NeuVax and other clinical milestone payments, as well as royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies.
On March 18, 2013, we acquired Abstral ® (fentanyl) Sublingual Tablets for sale and distribution in the United States from Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden. Abstral has been approved by the U.S. Food and Drug Administration (FDA) and is a transmucosal immediate-release fentanyl (TIRF) product.
Under our agreement with Orexo, we assumed responsibility for the U.S. commercialization of Abstral and for all regulatory and reporting matters in the U.S. We also agreed to establish and maintain through 2015 a specified minimum commercial field force to market, sell and distribute Abstral and to use commercially reasonable efforts to reach the specified sales milestones. Orexo is entitled to reacquire the U.S. rights to Abstral from us for no consideration if we breach our obligations to establish and maintain the requisite sales force throughout the marketing period. We expect to maintain our sales efforts beyond this date. We officially launched U.S. commercial sales of Abstral in October 2013.
Preferred Stock — The company has authorized up to 5,000,000 shares of preferred stock, $0.0001 par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the company’s board of directors upon its issuance. To date, the company has not issued any preferred shares.
Common Stock — The company has authorized up to 200,000,000 shares of common stock, $0.0001 par value per share, for issuance.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
ANR
¿Qué te hace pensar que es un chollo si no hace ningún gesto de recuperación? Yo solo interpreto que baja y baja
GALE
Demasiado bajista como para asumir riesgos?
